IP Library Granted Patent US 11,542,232
Granted Patent B2
US 11,542,232 · App. 16/798,160 · Granted Jan 3, 2023

Process for production of glycopyrronium tosylate

Inventors: Anthony Adrian Shaw (Redwood City, CA); Enrico Vigano (Milan, IT); Renato Molteni (Milan, IT)
Assignee: JOURNEY MEDICAL CORPORATION
C07D207/12B01D9/00C07C63/24C07C67/08C07C69/608C07C201/12C07C303/22C07C309/30C07C309/73C07F11/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,542,232
App. No.
16/798,160
Granted
Jan 3, 2023
Kind
B2
Abstract

Provided herein are methods for the production of glycopyrronium tosylate and glycopyrronium tosylate compositions. Also provided herein are compositions useful in the production of glycopyrronium tosylate. Additionally provided herein are glycopyrronium tosylate compositions. Glycopyrronium tosylate is useful for the treatment of, among other conditions, hyperhidrosis.

Claims (21)

1. A glycopyrrolate base composition comprising threo-glycopyrrolate base and erythro-glycopyrrolate base, wherein the threo-glycopyrrolate base is at least 95% of the total glycopyrrolate base content of the composition and the erythro-glycopyrrolate base is less than 5% of the total glycopyrrolate base content of the composition.

2. The glycopyrrolate base composition of claim 1 , wherein the threo-glycopyrrolate base is at least 96% of the total glycopyrrolate base content of the composition and the erythro-glycopyrrolate base is less than 4% of the total glycopyrrolate base content of the composition.

3. The glycopyrrolate base composition of claim 1 , wherein the threo-glycopyrrolate base is at least 97% of the total glycopyrrolate base content of the composition and the erythro-glycopyrrolate base is less than 3% of the total glycopyrrolate base content of the composition.

4. A glycopyrrolate base composition comprising threo-glycopyrrolate base and erythro-glycopyrrolate base, wherein the composition is produced by:

(i) contacting cyclopentylmandelic acid with 1-methylpyrrolidin-3-ol to form glycopyrrolate base:

(ii) contacting the glycopyrrolate base with 5-nitroisophthalic acid to form glycopyrrolate base, 5-nitroisophthalate salt:

and

(iii) contacting the glycopyrrolate base, 5-nitroisophthalate salt with an inorganic base to form glycopyrrolate base:

(iv) purifying the glycopyrrolate base obtained in step (iii) by contacting it with an organic solvent to obtain a purified glycopyrrolate base; wherein the organic solvent is a water-immiscible organic solvent.

5. A method of producing a glycopyrrolate tosylate composition comprising threo-glycopyrronium tosylate and erythro-glycopyrronium tosylate, wherein:

the threo-glycopyrronium tosylate is at least 95% of the total glycopyrrolate tosylate content of the composition;

the erythro-glycopyrronium tosylate is less than 5% of the total glycopyrrolate base content of the composition; and

the composition is produced by glycopyrronium base:

contacting the glycopyrronium base composition of claim 1 with methyl tosylate to produce glycopyrronium tosylate:

6. The method of claim 5 , wherein the threo-glycopyrronium tosylate is at least 96% of the total glycopyrronium tosylate content of the composition and the erythro-glycopyrronium tosylate is less than 4% of the total glycopyrronium tosylate content of the composition.

7. The method of claim 5 , wherein the threo-glycopyrronium tosylate is at least 97% of the total glycopyrronium tosylate content of the composition and the erythro-glycopyrronium tosylate is less than 3% of the total glycopyrronium tosylate content of the composition.

8. The method of claim 5 , wherein the threo-glycopyrronium tosylate is at least 99% of the total glycopyrronium tosylate content of the composition and the erythro-glycopyrronium tosylate is less than 1% of the total glycopyrronium tosylate content of the composition.

9. The method of claim 5 , wherein the threo-glycopyrronium tosylate is at least 99.5% of the total glycopyrronium tosylate content of the composition and the erythro-glycopyrronium tosylate is less than 0.5% of the total glycopyrronium tosylate content of the composition.

10. The method of claim 5 , wherein the threo-glycopyrronium tosylate is at least 99.6% of the total glycopyrronium tosylate content of the composition and the erythro-glycopyrronium tosylate is less than 0.4% of the total glycopyrronium tosylate content of the composition.

11. The composition of claim 4 , wherein the organic solvent is selected from a group consisting of: benzene, n-butanol, carbon tetrachloride, chloroform, cyclohexane, ethylene chloride, heptane, hexane, pentane, toluene, trichloroethylene, and xylene.

12. The composition of claim 11 , wherein the organic solvent is toluene.

Assignments (2)
SECURITY INTEREST Recorded Dec 28, 2023
From: JOURNEY MEDICAL CORPORATION; JG PHARMA, INC.
To: SWK FUNDING LLC
Reel/Frame 066157/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2021
From: DERMIRA, INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 056829/0767 →
Continuity (5)
Continuation 16370760 · Mar 29, 2019
Division 15895685 · Feb 13, 2018
Continuation 14830638 · Aug 19, 2015
Provisional Application 62039811 · Aug 20, 2014
Related Publication 20210002219A1 · Jan 7, 2021